Cargando…

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

PURPOSE: The subcutaneous (SC) administration of trastuzumab is highly preferred by patients. At home, administration of trastuzumab SC might further improve patient benefit. The aims of the BELIS study are to evaluate the safety and tolerability of trastuzumab SC when administered at home by a heal...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denys, Hannelore, Martinez-Mena, Corina L., Martens, Marc T., D’Hondt, Randal G., Graas, Marie-Pascale L., Evron, Ella, Fried, Georgeta, Ben-Baruch, Noa E., Vulsteke, Christof, Van Steenberghe, Mona M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182624/ https://www.ncbi.nlm.nih.gov/pubmed/32240454 http://dx.doi.org/10.1007/s10549-020-05604-7

Ejemplares similares

Andrei Bely : his life and works /
por: Mochulsky, K. (Konstantin), 1892-1948
Publicado: (1977)

Andrey Bely : a critical study of the novels /
por: Elsworth, J. D. (John David)
Publicado: (1983)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer
por: Wardley, Andrew, et al.
Publicado: (2021)

Species Designations Belie Phenotypic and Genotypic Heterogeneity in Oral Streptococci
por: Velsko, Irina M., et al.
Publicado: (2018)

India's COVID-19 emergency: overarching conclusions belie facts
por: Kumar, Dhavendra, et al.
Publicado: (2021)

Similarities in the Neural Control of the Shoulder and Elbow Joints Belie Their Structural Differences
por: Karduna, Andrew R., et al.
Publicado: (2012)

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2021)

Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy
por: Mortimer, Joanne, et al.
Publicado: (2014)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study
por: Vici, Patrizia, et al.
Publicado: (2014)

Present‐day sympatry belies the evolutionary origin of a high‐order polyploid
por: Wei, Na, et al.
Publicado: (2017)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study
por: Campiglio, M., et al.
Publicado: (2013)

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer
por: Yu, Y. F., et al.
Publicado: (2017)

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination
por: Swain, Sandra M., et al.
Publicado: (2019)

The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients
por: Stemmer, Salomon M., et al.
Publicado: (2013)

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer
por: Modi, Shanu, et al.
Publicado: (2013)

A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study
por: Lidbrink, Elisabet, et al.
Publicado: (2018)

Carboplatin dose capping affects pCR rate in HER2-positive breast cancer patients treated with neoadjuvant Docetaxel, Carboplatin, Trastuzumab, Pertuzumab (TCHP)
por: Howell, Sacha J., et al.
Publicado: (2020)

Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial
por: Wang, Zijing, et al.
Publicado: (2021)

The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
por: Takahashi, Masato, et al.
Publicado: (2020)

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
por: Marth, Christian, et al.
Publicado: (2022)

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab
por: Lin, Nancy U., et al.
Publicado: (2012)

Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

Genomic homogeneity between Mycobacterium avium subsp. avium and Mycobacterium avium subsp. paratuberculosis belies their divergent growth rates
por: Bannantine, John P, et al.
Publicado: (2003)

Erratum to: Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups
por: Netanely, Dvir, et al.
Publicado: (2016)

Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups
por: Netanely, Dvir, et al.
Publicado: (2016)

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
por: Stebbing, Justin, et al.
Publicado: (2021)

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)
por: Miles, David, et al.
Publicado: (2013)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2020)

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane
por: Pohlmann, Paula R., et al.
Publicado: (2022)

Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial
por: Hickish, Tamas, et al.
Publicado: (2022)

Limited overall impacts of ectomycorrhizal inoculation on recruitment of boreal trees into Arctic tundra following wildfire belie species-specific responses
por: Hewitt, Rebecca E., et al.
Publicado: (2020)

Marked Decrease in CA 19-9 Level Belies Rapidly Progressive Lymphangitic Carcinomatosis in a Case of Metastatic Pancreatic Cancer
por: King, Daniel A., et al.
Publicado: (2020)

First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811
por: Chung, Hyun Cheol, et al.
Publicado: (2020)

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study
por: Xu, Binghe, et al.
Publicado: (2022)

Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
por: Thill, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ijduh800t5lv942iotlgdslhvf